Newamsterdam Pharma N V (NAMS) Directors and Executive Officers - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Newamsterdam Pharma Company N v   (NASDAQ: NAMS)

Newamsterdam Pharma Company N v

Officers & Directors




Newamsterdam Pharma Company N v currently has 100 employees.

  News about Newamsterdam Pharma Company N v Key Personnel

NewAmsterdam Pharma Seeks Recovery Amid Financial Losses and Promising Clinical Trials for Obicetrapib,

NewAmsterdam Pharma Looks Forward Amidst Financial Losses and Promising Cardiovascular ResearchBy CSI MarketAs NewAmsterdam Pharma Company N.V. strides into 2025, the company s ambitions remain remarkably high despite the turbulence reflected in its recent financial performance. With a reported cumulative net loss of $133 million by the third quarter of 2024 and a striking negative return on investment (ROI) of -34.83%, the outlook for the innovative pharmaceutical company is a mix of promise and concern.The key driver of NewAmsterdam s optimism lies in obicetrapib, their flagship oral, non-statin lipid-lowering therapy, which is at the forefront of clinical trials intended to tackle one of the most pre...

NewAmsterdam Pharma Bolsters Team to Revolutionize Cardiovascular Disease Treatment,


Summary:
NewAmsterdam Pharma Company N.V. a leading clinical biopharmaceutical company based in the Netherlands, disclosed the approval of inducement grants for three non-executive new hires. These grants, intended to attract top talent to the company, are crucial for NewAmsterdam s mission of developing effective and well-tolerated oral medications for patients at high risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C). This move aligns with the company s 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Let s delve into the facts and assess the impact on the company and its promising endeavors.
The Details:
Naarden, the Netherlands, and Mi...

NewAmsterdam Pharma Employs Inducement Share Options to Attract Top Non-Executive Talent for Pioneering CVD Research

NewAmsterdam Pharma Grants Inducement Share Options to Non-Executive New Hires
NewAmsterdam Pharma Company N.V., a clinical biopharmaceutical company based in the Netherlands and Miami, has recently approved the grant of inducement share options to three non-executive new hires. The company focuses on developing oral, non-statin medications for individuals at risk of cardiovascular disease (CVD) with elevated levels of low-density lipoprotein cholesterol (LDL-C), for whom current treatments are not effective or well-tolerated.
The Compensation Committee of NewAmsterdam s Board of Directors made the decision to grant share options as an inducement to these new employees. In total, 30,000 ordinary sha...






NAMS Management Effectiveness NAMS Revenue per Employee NAMS Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.